Company / Financials
Lexeo Therapeutics, Inc. Financials
FY2023-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableRevenue
$654.0K
FY2023 · NaN% YoY
Net Income
-$59.3M
FY2023 · NaN% YoY
Profit Margin
-9063.8%
FY2023 · net income / revenue
ROE
-
FY2023 · return on equity
Total Assets
$139.8M
FY2023
Total Debt
-
FY2023
Equity
-$113.0M
FY2023
ROA
-42.4%
FY2023 · return on assets
Statement paths
Financial highlights
Key Data Points
- Low Piotroski F-Score: 1/9 (multiple financial health concerns)
- Altman Z-Score -0.98 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Metric history
Revenue HistoryTotal revenue from operations$654.0KNet Income HistoryProfit after all expenses and taxes-$59.3MOperating Income HistoryProfit from core business operations before interest and taxes-$60.5MSG&A Expense HistorySelling, general, and administrative expenses$12.0MR&D Expense HistoryResearch and development spending$49.2MInterest Expense HistoryCost of borrowing and debt obligations$91.0KEPS (Basic) HistoryBasic earnings per share-$36.36EPS (Diluted) HistoryDiluted earnings per share including stock options and convertibles-$36.36Shares Outstanding HistoryWeighted average diluted shares outstanding1.6MTotal Assets HistoryTotal value of all assets owned$139.8M